Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 2004 Jan;42(1):7–11. doi: 10.1128/JCM.42.1.7-11.2004

Identification and Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa by Direct Inoculation from Positive BACTEC Blood Culture Bottles into Vitek 2

Marjan J Bruins 1,*, Peter Bloembergen 1, Gijs J H M Ruijs 1, Maurice J H M Wolfhagen 1
PMCID: PMC321735  PMID: 14715724

Abstract

Inoculation of an automated system for rapid identification (ID) and antimicrobial susceptibility testing (AST) directly from positive blood culture bottles will reduce the turnaround time of laboratory diagnosis of septicemic patients, which benefits clinical outcome and decreases patient costs. Direct test results, however, must always be confirmed by testing a pure overnight culture, which is the “gold standard.” We studied the accuracy of direct testing versus repeat testing in order to investigate the possibility of refraining from repeat testing. We also assessed the clinical risk of reporting results based on direct testing only. We inoculated Vitek 2 (bioMérieux) directly from 410 positive BACTEC 9240 (BD) blood culture bottles containing gram-negative rods and studied the ID and AST results. In a comparison of direct inoculation with the standard method, a total of 344 isolates of Enterobacteriaceae and Pseudomonas aeruginosa were tested, and 93.0% were correctly identified. Of the 39 (10.2%) samples that contained bacilli not identifiable by Vitek 2, only 1 gave a conclusive, correct result. The overall MIC agreement among 312 isolates was 99.2%, with 0.8% very major and 0.02% major error rates. Of only three (polymicrobial) samples, the direct susceptibility pattern would be reported to the clinician as too sensitive. Vitek 2 results obtained from direct inoculation of blood culture bottles containing gram-negative bacilli are safe enough for immediate reporting, provided that ID and AST are consistent. Repeat testing is not necessary, unless Gram stain or overnight subculture results raise doubt about the purity of the culture.


Shortening the turnaround time of microbiological analyses with an automated system for rapid identification and susceptibility testing of bacteria leads to a significant reduction of patient morbidity, mortality, and cost (1, 2). In particular, for patients with septicemia, rapid laboratory results are essential for appropriate treatment and improving clinical outcome (21). An automated blood culture system that monitors culture bottles for microbial growth minimizes the time necessary to detect positive blood cultures. Another way to save time might be to inoculate an automated system for rapid identification and susceptibility testing directly from positive blood culture bottles. The conventional way is to wait for the overnight subculture on agar to prepare a standard inoculum according to the manufacturer's guidelines.

Of all bacteria involved in bloodstream infections, the fast-growing Enterobacteriaceae will probably produce the quickest and best-correlating results for direct and standard inoculation. Several studies have compared direct and standard methods for different (combinations of) automated systems, but to our knowledge no study has yet done this for Vitek 2 (7, 8, 18, 20, 22).

We routinely inoculate Vitek 2 directly from BACTEC 9240 blood culture bottles that are positive for gram-negative rods. To check the direct results, we repeat the tests the next day with suspensions made from pure cultures according to the Vitek 2 manufacturer's instructions.

The two aspects we studied were (i) the accuracy of direct testing versus standard (repeat) testing in order to be able to refrain from repeat testing and (ii) the clinical risk of an approach using results of direct testing only.

MATERIALS AND METHODS

Samples.

The Laboratory of Clinical Microbiology and Infectious Diseases of the Isala Klinieken, a 1,100-bed, multisite hospital in Zwolle, The Netherlands, processes ∼9,500 blood cultures yearly by using the BACTEC 9240 system (software version V4.40A; culture bottles PLUS Aerobic/F and PLUS Anaerobic/F [BD, Erembodegem-Aalst, Belgium]). The data were collected from November 2000 to March 2003; during this period, every blood culture positive for gram-negative bacilli was inoculated into Vitek 2 directly, preferably from the aerobic bottle. Per patient, every first positive culture of a septicemic episode containing gram-negative rods that appeared to be monomicrobial on Gram staining was included in the study.

VT2.

The Vitek 2 system (Vitek 2 software, version R02.03; Advanced Expert System [AES] software, version R02.00N [bioMérieux, Marcy l'Étoile, France]) was used with the ID-GNB card and the AST-N020 card for identification (ID) and antimicrobial susceptibility testing (AST), respectively, of gram-negative bacilli. The antimicrobial agents tested were amikacin, amoxicillin-clavulanic acid, ampicillin, cefalotin, cefepime, cefotaxime, cefoxitin, cefpodoxime, ceftazidime, cefuroxime, ciprofloxacin, gentamicin, meropenem, nitrofurantoin, norfloxacin, ofloxacin, piperacillin, piperacillin-tazobactam, tobramycin, and trimethoprim-sulfamethoxazole.

Vitek 2 identifies gram-negative rods within 3 h at the species level by interpreting 41 fluorescent biochemical tests. If the biopattern does not match one particular taxon in the database, results are reported as “low discrimination” (2 to 3 taxa), “inconclusive” (>3 taxa), or “unidentified” (no match). Ambiguous results due to slowly metabolizing nonfermenters are reported as “various nonfermenting gram-negative bacilli.”

Susceptibility testing takes 5 to 19 h to obtain complete results. Vitek 2 needs a conclusive ID to establish and report definitive results. The AES analyzes whether ID and susceptibility data are consistent by consulting the phenotype descriptions in the database and, if necessary, recommends a correction in a MIC to complete the biological validation. The AES may also suggest a change in an interpretation from sensitive (S) to intermediate (I) or resistant (R), based on recognized resistance mechanisms, to prevent therapeutic failure. These changes of interpretation are according to the software parameters defined by the user (19). For the tests in the present study, interpretations as recommended by the National Committee for Clinical Laboratory Standards (15) and the AES configuration parameters set “natural resistance,” “European hospitals,” “never more susceptible,” and “least risk” were used. The AES knowledge base contains phenotypes of most Enterobacteriaceae and of Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia cepacia, Pasteurella multocida, and Stenotrophomonas maltophilia (only trimethoprim-sulfamethoxazole). If a species other than these is identified, expert analysis cannot be completed. For this reason, if the standard inoculation method is used, in our laboratory we inoculate Vitek 2 according to the manufacturer's instruction, but only with isolates that are suspected of being Enterobacteriaceae or P. aeruginosa, based on their appearance on (differential) agar media and biochemical reactions such as the oxidase test.

Direct method.

A serum separator tube (BD Vacutainer Systems, Plymouth, United Kingdom) was aseptically inoculated with 4 ml from a positive BACTEC 9240 bottle by using a 5-ml syringe, and a Gram stain was done. If the culture contained gram-negative rods and appeared to be monomicrobial, the tube was centrifuged at 1,525 × g for 10 min, and the supernatant was carefully aspirated. With a cotton swab, the film of bacteria on top of the gel layer was removed and used to make a 0.5 to 0.63 McFarland suspension in 3 ml of 0.45% saline (modification of Waites et al. [22]). The suspension was processed according to the standard Vitek 2 inoculation procedure.

Standard method.

Some of the blood culture fluid was inoculated onto a combination of agar plates, suited for culturing aerobic, anaerobic, and fastidious microorganisms. After overnight incubation, several colonies of isolates suspected of being Enterobacteriaceae or P. aeruginosa were used to make a 0.5 to 0.63 McFarland suspension in 0.45% saline. The suspension was processed according to standard Vitek 2 inoculation procedure.

Quality control.

Weekly ID-GNB and AST-N020 cards were tested once each with Klebsiella oxytoca strain ATCC 700324 and Escherichia coli strain ATCC 25922, respectively.

Data analysis.

Direct and standard inoculation were compared for Enterobacteriaceae and P. aeruginosa, except for AST of Pantoea spp., for which genus the AES does not contain expert data.

The Vitek 2 standard method results were used as the gold standard for ID testing, except in a few cases where the API system was necessary to provide the definitive identification. The Vitek 2 identifications Klebsiella pneumoniae subsp. pneumoniae (planticola/terrigena) and K. pneumoniae subsp. ozaenae were considered identical and reported as K. pneumoniae; K. oxytoca and K. oxytoca (planticola/terrigena) were reported as K. oxytoca. Our category “not identified” includes the Vitek 2 reports “inconclusive,” “unidentified,” and “terminated.”

For susceptibility testing, we compared direct and standard inoculation only of isolates with results biologically validated by Vitek 2 for both methods. The standard method results were considered the gold standard.

The MIC agreement (direct MIC within one twofold dilution of the standard MIC) (14) without any changes made by the AES and discrepancies in interpretation after AES analysis were determined for each antibiotic. A minor error was defined as a susceptibility result of “I” by the direct method and “S” or “R” by the standard method or “I” by the standard method and “S” or “R” by the direct method. A major error was defined as “R” by the direct method and “S” by the standard method, and a very major error was defined as “S” by the direct method and “R” by the standard method.

We also assessed the outcome of direct testing of blood cultures containing anaerobic, fastidious, and other gram-negative bacilli not identifiable by Vitek 2. We investigated whether these results could lead to misleading reports if reporting was based on direct testing only. For these isolates standard diagnostic methods such as the API system (bioMérieux) were used for identification.

If the agar plate culture of an apparently monomicrobial sample yielded two or more different species, we evaluated the therapeutic risk involved in the immediate reporting of the direct (mixed) susceptibility pattern.

RESULTS

Of the 410 blood cultures that met the study inclusion criteria, results of direct inoculation of six samples could not be retrieved because of missing or deleted data (n = 2), omission of direct testing (n = 1),or Vitek 2 malfunction (n = 1). Twenty-one samples (5.1%) that appeared to be monomicrobial in the Gram stain yielded more than one isolate in the blood bottle's subculture. Table 1 lists the results of 383 direct identifications from monomicrobial blood cultures. In all, 39 (10.2%) samples contained anaerobic, fastidious, or gram-positive bacilli or nonfermenting gram-negative rods other than P. aeruginosa. Of these, only one strain of S. maltophilia gave a conclusive result. Of 311 Enterobacteriaceae and 33 P. aeruginosa strains, 93.0% (320 of 344) were correctly identified, 2.6% (9 of 344) were reported as “low discrimination,” 2.3% (8 of 344) were not identified, and 2.0% (7 of 344) were misidentified according to our definitions. The five most frequently isolated species were E. coli, P. aeruginosa, K. pneumoniae, Proteus mirabilis, and Enterobacter cloacae.

TABLE 1.

Results of direct inoculation of Vitek 2 ID-GNB card from blood cultures containing monomicrobial gram-negative rods

Organism group and namea No. of strains
Tested Correctly identified Low discrimination Not identifiedb Misidentified (misidentification)d
Nonfermentersc
    Acinetobacter spp. 4 1 3 (VNGNB)
    Alcaligenes spp. 3 1 2 (VNGNB)
    Brevundimonas spp. 1 1
    Flavimonas spp. 1 1
    Ochrobactrum spp. 1 1
    Pseudomonas stutzeri 1 1 (VNGNB)
    Ralstonia pickettii 1 1 (VNGNB)
    Stenotrophomonas maltophilia 3 1 1 1
Anaerobic gram-negative rods
    Bacteroides spp. 14 14
    Fusobacterium spp. 2 2 (VNGNB)
Fastidious gram-negative rods
    Haemophilus influenzae 6 2 4
    Streptobacillus moniliformis 1 1 (VNGNB)
Gram-positive rods
    Clostridium spp. 1 1
Enterobacteriaceae
    Citrobacter koseri 1 1
    Citrobacter freundii 3 2 1
    Enterobacter aerogenes 2 2
    Enterobacter cloacae 21 20 1
    Enterobacter sakazakii 1 1 (Enterobacter cloacae)
    Escherichia coli 188 183 3 1 (VNGNB), 1 (Klebsiella oxytoca)
    Ewingella americana 1 1
    Klebsiella oxytoca 13 13
    Klebsiella pneumoniae 30 26 1 3
    Leclercia adecarboxylata 1 1
    Morganella morganii 4 3 1 (Bergeyella zoohelcum)
    Pantoea spp. 3 1 1 1
    Proteus mirabilis 25 25
    Salmonella spp. 7 6 1
    Serratia marcescens 11 11
Pseudomonas aeruginosa 33 26 3 1 3 (VNGNB)
Total 383 321 16 29 17
a

Names determined by Vitek 2 standard method or API system.

b

Includes Vitek 2 reports “unidentified,” “inconclusive,” and “terminated.”

c

Other than Pseudomonas aeruginosa.

d

VNGNB, various nonfermenting gram-negative bacilli.

Of the 320 correctly identified isolates of Enterobacteriaceae and P. aeruginosa, 8 were excluded from AST evaluation due to termination or omission of the standard method AST (n = 4), a standard method identification result of “low discrimination” (n = 2), an inconsistent direct ID and susceptibility pattern combination (n = 1), or identification as Pantoea spp. (no expert analysis possible) (n = 1). In all, 6,477 MICs were determined for 312 isolates by both methods. MIC agreement and interpretation discrepancies are shown in Table 2. The overall MIC agreement between direct and standard inoculation was 99.2%. Except for piperacillin (95.2%), all individual antimicrobial agents scored as ≥98.7%.

TABLE 2.

MIC agreement and errors for antimicrobial agents between direct and standard methoda

Antimicrobial agent No. of tests MIC agreement
Error
MIC unagreement MIC agreement % MIC agreement Minor Major Very major
Amikacin 302 0 302 100.0 1 0 0
Amoxicillin-clavulanic acid 311 4 307 98.7 4 0 0
Ampicillin 312 2 310 99.4 2 1 0
Cefalotin 311 3 308 99.0 15 0 0
Cefepime 301 0 301 100.0 0 0 0
Cefotaxime 310 4 306 98.7 5 0 2
Cefoxitin 301 0 301 100.0 4 0 0
Cefpodoxime 301 4 297 98.7 1 0 0
Ceftazidime 311 2 309 99.4 1 0 1
Cefuroxime 310 4 306 98.7 17 0 0
Cefuroxime axetil 300 4 296 98.7 24 0 0
Ciprofloxacin 311 0 311 100.0 0 0 0
Gentamicin 312 3 309 99.0 2 0 0
Meropenem 311 0 311 100.0 0 0 0
Nitrofurantoin 312 3 309 99.0 30 0 0
Norfloxacin 312 2 310 99.4 5 0 0
Ofloxacin 311 0 311 100.0 1 0 0
Piperacillin 312 15 297 95.2 17 0 3
Piperacillin-tazobactam 312 3 309 99.0 3 0 0
Tobramycin 302 0 302 100.0 1 0 0
Trimethoprim-sulfamethoxazole 312 0 312 100.0 0 0 0
Total 6,477 53 (0.8) 6,424 (99.2) 133 (2.1) 1 6
a

Values in parentheses are percentages.

Most minor discrepancies occurred with cefalotin, nitrofurantoin, piperacillin, and cefuroxime. The overall minor error rate was 2.1% (133 of 6,477). Only one major error occurred for E. coli tested against ampicillin, which yielded an overall major error rate of 0.02% (1 of 6,477). Six very major errors occurred, which yielded an overall very major error rate of 0.1% (6 of 6,477). Murray et al. recommend calculating major and very major rates by dividing the number of discrepancies by the number of strains tested as sensitive and resistant, respectively, with the reference method (12, 13). According to this calculation, the major error rate would be 0.02% (1 of 5,508) and the very major error rate would be 0.8% (6 of 748). The very major errors were distributed among two isolates of E. cloacae and two isolates of E. coli and concerned test results associated with piperacillin, cefotaxime, and ceftazidime.

Of the 21 polymicrobial samples, 11 (52.4%) identifications yielded an unambiguous and conclusive result. For three of these samples, the AST results were reported as inconsistent; for one, they were terminated. Of the other seven samples with a falsely conclusive ID, three were reported with the susceptibility pattern of the most sensitive bacillus. One of these samples contained K. oxytoca and P. aeruginosa; the other two both contained two different phenotypes of E. coli.

DISCUSSION

In our study we focused on the direct inoculation of blood cultures containing gram-negative bacilli. Because in our experience direct inoculaton of gram-positive cultures yielded unsatisfactory results, we discontinued this after a trial period (data not shown).

We used the Vitek 2 standard method as the gold standard for comparing direct and standard ID and AST results of Vitek 2 identifiable isolates, since its performance has been compared to reference methods extensively and with good results (4, 5, 6, 10). In a few instances the API system helped out where the standard ID was inconclusive.

Routinely, we inoculate Vitek 2 only with isolates suspected of being Enterobacteriaceae or P. aeruginosa grown in pure culture from agar plates, for which the AES knowledge base contains the data to complete expert analysis of the AST. Although for ID testing Vitek 2 is approved by the Food and Drug Administration for a much larger range of gram-negative rods, in our experience and that of others its performance is best for identifying bacilli belonging to these groups (4, 6, 10). Therefore, direct and standard results of these species only (except Pantoea spp.) were compared; all other gram-negative bacilli were considered not identifiable by Vitek 2.

Direct inoculation of blood cultures containing gram-negative bacilli indistinguishable from organisms identifiable by Vitek 2 in the Gram stain might cause misleading reports. However, in the present study, none of the isolated anaerobic, fastidious, or gram-positive bacilli or nonfermenters, other than P. aeruginosa, yielded an unambiguous Vitek 2 ID result, except for S. maltophilia, which was correctly identified.

With the direct method, 93.0% of Enterobacteriaceae and P. aeruginosa strains together and 94.5% of Enterobacteriaceae strains alone were correctly identified. For selecting a new system for identification, at least 90% overall agreement with a reference system and at least 95% accuracy in identifying commonly isolated organisms such as Enterobacteriaceae are recommended (13). We view our results as more than acceptable, since they are consistent with this and with the percentages determined in studies comparing Vitek 2 (used according to standard protocol) to reference methods (4, 6, 10, 16).

The top five most frequently isolated bacilli (E. coli, P. aeruginosa, K. pneumoniae, P. mirabilis, and E. cloacae) are similar to those reported from the United States and Canada and from Europe (3, 17).

The strains of Enterobacteriaceae or P. aeruginosa misidentified as Bergeyella zoohelcum and various nonfermenting gram-negative bacilli (no expert analysis possible) would be retested from a subculture before being reported. Enterobacter sakazakii identified as E. cloacae would not lead to inappropriate antimicrobial treatment. Probably a too-low inoculum was responsible for the misidentification of E. coli as K. oxytoca.

The overall 99.2% MIC agreement between direct and standard susceptibility testing was very high. For every antimicrobial agent the MIC agreement was >90%, as required by the selection criteria for an antimicrobial susceptibility testing system proposed by Jorgensen (9).

Overall, error rates were very low (major, 0.02%; very major, 0.8%). A too-low inoculum probably caused very major errors with direct testing of piperacillin, cefotaxime, and ceftazidime for only four isolates. The falsely sensitive results with cefotaxime and ceftazidime for E. cloacae would be of no consequence, since Enterobacter spp. capable of producing an inducible betalactamase would not be treated with any of these drugs.

Only 5.1% of the 410 samples inoculated directly into Vitek 2 were found to be polymicrobial when subcultured, which does not differ from other findings (11, 22). In seven samples there would have been a false report. Their identification and AST results were conclusive and consistent, so the fact that the cultures were not pure would not have been recognized. Of these, only three were reported with too-sensitive AST results, probably because of a lower inoculum or slower growth rate of the more resistant strain in the mixed culture.

We found that direct inoculation of Vitek 2 from BACTEC 9240 blood culture bottles to analyze gram-negative bacilli involved in bloodstream infection is safe enough for immediate reporting, provided that ID and AST are conclusive and consistent. Repeat testing by the standard method seems necessary only, if subculturing of the bottle yields isolates suspected of being Enterobacteriaceae or P. aeruginosa and the direct results are inconclusive. Nevertheless, direct inoculation should not be applied when the Gram stain raises any doubt about the purity of the culture.

Acknowledgments

We thank bioMérieux for technical help in retrieving Vitek 2 data and Helen Klip and Teun Groenendijk for help in data analysis.

REFERENCES

  • 1.Barenfanger, J., C. Drake, and G. Kacich. 1999. Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing. J. Clin. Microbiol. 37:1415-1418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Doern, G. V., R. Vautour, M. Gaudet, and B. Levy. 1994. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J. Clin. Microbiol. 32:1757-1762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fluit, A. C., M. E. Jones, F.-J. Schmitz, J. Acar, R. Gupta, J. Verhoef, and the SENTRY participants group. 2000. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin. Infect. Dis. 30:454-460. [DOI] [PubMed] [Google Scholar]
  • 4.Funke, G., D. Monnet, C. deBernardis, A. von Graevenitz, and J. Freney. 1998. Evaluation of the VITEK 2 system for rapid identification of medically relevant gram-negative rods. J. Clin. Microbiol. 36:1948-1952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Garcia-Garrote, F., E. Cercenado, and E. Bouza. 2000. Evaluation of a new system, VITEK 2, for identification and antimicrobial susceptibility testing of enterococci. J. Clin. Microbiol. 38:2108-2111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gavin, P. J., J. R. Warren, A. A. Obias, S. M. Collins, and L. R. Peterson. 2002. Evaluation of the Vitek 2 system for rapid identification of clinical isolates of gram-negative bacilli and members of the family streptococcaceae. Eur. J. Clin. Microbiol. Infect. Dis. 21:869-874. [DOI] [PubMed] [Google Scholar]
  • 7.Hansen, D. S., A. G. Jensen, N. Norskov-Lauritsen, R. Skov, and B. Bruun. 2002. Direct identification and susceptibility testing of enteric bacilli from positive blood cultures using VITEK (GNI+/GNS-GA). Clin. Microbiol. Infect. 8:38-44. [DOI] [PubMed] [Google Scholar]
  • 8.Howard, W. J., B. J. Buschelman, M. J. Bale, M. A. Pfaller, F. P. Koontz, and R. N. Jones. 1996. Vitek GPS card susceptibility testing accuracy using direct inoculation from BACTEC 9240 blood culture bottles. Diagn. Microbiol. Infect. Dis. 24:109-112. [DOI] [PubMed] [Google Scholar]
  • 9.Jorgensen, J. H. 1993. Selection criteria for an antimicrobial susceptibility testing system. J. Clin. Microbiol. 31:2841-2844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ling, T. K., P. C. Tam, Z. K. Liu, and A. F. Cheng. 2001. Evaluation of VITEK 2 rapid identification and susceptibility testing system against gram-negative clinical isolates. J. Clin. Microbiol. 39:2964-2966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Moore, D. F., S. S. Hamada, E. Marso, and W. J. Martin. 1981. Rapid identification and antimicrobial susceptibility testing of gram-negative bacilli from blood cultures by the AutoMicrobic system. J. Clin. Microbiol. 13:934-939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Murray, P. R., A. C. Niles, and R. L. Heeren. 1987. Comparison of a highly automated 5-h susceptibility testing system, the Cobas-Bact, with two reference methods: Kirby-Bauer disk diffusion and broth microdilution. J. Clin. Microbiol. 25:2372-2377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1999. Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
  • 14.National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  • 15.National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  • 16.O'Hara, C. M., and J. M. Miller. 2003. Evaluation of the Vitek 2 ID-GNB assay for identification of members of the family Enterobacteriaceae and other nonenteric gram-negative bacilli and comparison with the Vitek GNI+ card. J. Clin. Microbiol. 41:2096-2101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Pfaller, M. A., R. N. Jones, G. V. Doern, K. Kugler, and the Sentry participants group. 1998. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42:1762-1770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Putnam, L. R., W. J. Howard, M. A. Pfaller, F. P. Koontz, and R. N. Jones. 1997. Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: use of “direct” inoculation from Bactec 9240 blood culture bottles. Diagn. Microbiol. Infect. Dis. 28:101-104. [DOI] [PubMed] [Google Scholar]
  • 19.Sanders, C. C., M. Peyret, E. Smith Moland, S. J. Cavalieri, C. Shubert, K. S. Thomson, J.-M. Boeufgras, and W. E. Sanders, Jr. 2001. Potential impact of the VITEK 2 system and the advanced expert system on the clinical laboratory of a university-based hospital. J. Clin. Microbiol. 39:2379-2385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Stager, C. E., and J. R. Davis. 1992. Automated systems for identification of microorganisms. Clin. Microbiol. Rev. 5:302-327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Trenholme, G. M., R. L. Kaplan, P. H. Karakusis, T. Stine, J. Fuhrer, W. Landau, and S. Levin. 1989. Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates. J. Clin. Microbiol. 27:1342-1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Waites, K. B., E. S. Brookings, S. A. Moser, and B. L. Zimmer. 1998. Direct Susceptibility testing with positive BacT/Alert blood cultures by using MicroScan overnight and rapid panels. J. Clin. Microbiol. 36:2052-2056. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES